Skip to Content

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

The FRESCO-2 phase III trial evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer is one of several studies Marco Gerlinger, Professor of Gastrointestinal Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University of London present in this MEDtalk with highlights from ESMO for treatment of lower gastrointestinal tumors.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top